SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
VPHM Analysis & Videos »
VPHM: Bull or Bear?
FDA Calendar Updates: MELA, PGNX, VPHM, WYE
VPHM
|
|
|
+2.95%
in
99 days
<> Below is a summary of updates to the <font> BioMedReports.com FDA Calendar </font> , which includes a database of 288 entries as of 8/5/09. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of BioMedReports.com, the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, ANDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the FDA, and pending late-stage cli...
|
A New Global Healthcare Composite Index
VPHM
|
|
|
-41.80%
in
204 days
(closed on 08/05/09)
<> 
The accompanying table [click to enlarge] presents the top five rated companies with market caps of at least $100M from each of the eight new ETF Innovators healthcare indexes, including a database exceeding 500 companies worldwide. The Healthcare Composite Index is a dynamic, semi-active index with quarterly rebalancing which consists of the 40 top-rated companies on an equal weight basis from each of the eight global healthcare indexes listed below and represents an alternative strategy to existing health composite ETF...
|
A New Index of Health Product Innovators
VPHM
|
|
|
-6.57%
in
8 days
(closed on 01/13/09)
<> 
The accompanying table includes statistics and all 23 companies in the ETF Innovators [ETFI] Global Health Innovators Index of companies with market caps over $250M which received FDA approval in the past 12 months for an original new drug product or medical device.
The index includes companies which get approvals for drugs or biological agents classified as new chemical entities (i.e. excluding all new formulations of existing drugs, generic drugs, and label extensions for existing products). Also, companies whi...
|
FDA Calendar: A Weekly Update
VPHM
|
|
|
+15.13%
in
30 days
(closed on 01/05/09)
<> 
The accompanying table [click to enlarge] presents an updated calendar of 73 expected FDA decision dates as part of the ETF Innovators [ETFI] New Drug Regulatory Catalyst Index. Below is a summary of the FDA action over the past week.
1.) ViroPharma (VPHM) – Filed a sBLA on 12/1/08 to expand use of Cinryze C1 Inhibitor (human) as a treatment for acute attacks of hereditary angioedema [HAE], which is already FDA approved for regular use in the prevention of angioedema attacks in adolescent and adult patients with HAE. Standa< />< />< />< /><>< />< />< />< />< />< />< />< /><>< />< />< />< /><>...
|
ETFI Health Innovators Index: Does R&D Lead to Higher Stock Prices?
VPHM
|
|
|
+7.69%
in
23 days
(closed on 12/05/08)
<> 
<> The accompanying table includes statistics and the top five rated companies in the ETFI Global Health Innovators Index of companies with market caps over $100M which received FDA approval in the trailing 12-month period for either an original new drug or medical device product. The index includes companies which get approvals for drugs or biological agents classified as new chemical entities (i.e. excluding reformulations of existing drugs, generic drugs, and label extensions for existing produc...
|
ViroPharma Value Worth Buying
VPHM
-28.38%
in
505 days
ViroPharma could be a dramatically different-looking company in 2010 if pipeline antiviral candidate Camvia succeeds in treating cytomegalovirus disease.
|
ViroPharma: Cheap Cheap Cheap
VPHM
|
|
|
-16.63%
in
663 days
This company has great cash flow, a great product line, very profitable and is frankly in the right spot at the right time. A primary focus is antibiotic resistant strep (a growing concern in the US). The company has a P/E of 7.5 which more than qualifies it as a value stock. Recently this stock has been talked about by several small cap managers on CNBC and Bloomberg showing that it is finally starting to be noticed.
Disclosure: I do not hold this stock personally but several of my client do.
|
Camvia & Vancocin & The Baker Brothers
VPHM
|
|
|
-3.88%
in
731 days
Reasons to buy: 1. Baker Brothers bought 900,000 shares on Nov 8,2007 2. Camvia Phase III trials could be very promising with FDA Orphan status 3. Possible increase in demand for Vancocin even with generic due out in 2008?
|
People Bullish on VPHM
People Bearish on VPHM
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
| StreetInsider.com on VPHM |
Morning Movers 10/28: CSBC, QTM, ANIK, RSYS, PEET, WSII Higher; CALC, KSP, PSYS, VCLK, VPHM, GT Lower
Be the first to start a discussion and earn 2 points.
More Resources
|
